Scholarly Works - Book sections
Book section
·
January 1, 2019
Carcinoma of unknown primary (CUP) is a diverse group of heterogeneous cancers presenting without a primary site and accounts for about 2% to 4% of all cancers. The past two decades have seen significant change in our approach to CUP patients. Therapy stra ...
Full text
Cite
Book section
·
April 11, 2018
Pancreatic adenocarcinoma is one of the most lethal cancers but has limited therapeutic options necessitating continued investigation of new therapeutic agents. Recently, improved overall survival has been achieved with cytotoxic drug combinations includin ...
Full text
Cite
Book section
·
October 30, 2015
As we learn more about the molecular underpinnings of pancreatic cancer, we are discovering new growth pathways that present opportunities for treatment. KRAS represents one such target. Activating mutations, found in the majority of pancreatic cancer, act ...
Full text
Cite
Book section
·
December 1, 2008
Pancreatic cancer is a systemic disease for most patients, and two-thirds of patients have locally advanced or metastatic disease at the time of diagnosis. For the subset of patients (20%) who present with potentially resectable tumors, the 5-year survival ...
Full text
Cite
Book section
·
January 1, 2007
The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combinati ...
Full text
Cite
